APP vaccinontwikkeling (BO-20-009-001, BO-08-013-002)

Reverse genetics for African horsesickness virus (AHSV) was developed. The method was subsequently used to exchange the serotype-determining genome segment for all nine serotypes in well-producible AHSV. The method was also used to knock-out the NS3-expression. A serology test detecting antibodies against this immunogenic protein is currently under development by others. On this way, two sets of viruses were generated  for all nine serotypes. These can be used for production of dead AHS vaccines and for the production of live-attenuated vaccines, since the ancestor virus has been applied in both ways during the Spanish AHS outbreak.

In addition, a lot of knowledge as generated by research on the related Bluetongue virus  was used. Similar to BT DISA vaccine for Bluetongue (DISA: Disabled Infectious Single Animal: patent application 16 may 2013), AHSV variants without NS3 expression are very promising candidates for the development of AHS DISA vaccines.

 

Description problem/question

Vaccine for AHS is not available

 

Research objectives

Vaccine development for African horse sickness

 

Results and products

Exchange method for AHSV

Production viruses for six serotypes of AHSV

AHS-vaccine candidates based on inactivated AHSV